Client News

A new analysis from Abernathy Daley reveals that 84% of U.S. 401(k) plans show at least one red flag indicating potential ERISA violations. The findings highlight widespread fiduciary compliance concerns with serious implications for plan sponsors and participants. In a recent interview, CEO Steven Abernathy points to the lack of qualified default investment alternatives (QDIAs) as the most common, and most risky, oversight.

After several years defined by contraction, austerity, and widespread layoffs, Silicon Valley is experiencing a spirited resurgence, this time fueled by the explosive growth and promise of AI. In a recent feature, Business Insider spotlighted the momentum behind this revival, curating a list of technology and AI startups that are not just surviving but scaling. Among the standout names is Cohere Health, which secured a $50 million Series B extension in February 2024.

This 401k Real Talk episode discusses how the DC industry remains slow in adopting AI due to outdated tools, while partnerships like Orion’s with Pontera may provide more holistic financial planning options for wealth advisors. Additionally, private equity firms, including KKR and Apollo, are increasingly eyeing the $11 trillion DC market while concerns over regulatory and fiduciary issues in DC plans continue to rise.

Small-molecule CDMOs face challenges like funding cuts, supply chain disruptions, and growing demand, yet they remain essential in balancing supply and demand, driving innovation, and improving patient outcomes. This article discusses that in order to thrive, they must continue embracing innovation, streamlining operations, and ensuring flexibility and scalability in their production processes, while focusing on patient-centric drug discovery and integrating advanced manufacturing technologies.

This conversation was about the implications of the 2025 CMS Final Rule for the home care industry. Key insights include that home care providers are facing rising costs and staffing challenges, but payment increases from CMS have been minimal, only around 0.5%. Technology and automation, such as leveraging AI for documentation, can help home care providers become more scalable and efficient.

America’s healthcare system is under financial strain due to rising levels of uncompensated care, with patient debt contributing to delayed treatments and poorer health outcomes. This article explores how healthcare organizations must adopt strategies like financial assistance programs, improved revenue cycle management, and strengthened patient engagement to address this.

Many employers overlook the importance of regular 401(k) benchmarking audits, which can lead to costly plans and legal risks. By conducting these audits, companies can improve plan offerings, reduce fees, and ensure better financial outcomes for employees, ultimately benefiting both the workforce and the company's reputation.

Retailers are forecasted to hire between 400,000 to 500,000 seasonal workers to keep up with increased consumer activity this holiday season. Seasonal hiring is different from regular hiring due to the time crunch, high volume of applicants, and need for quick onboarding. Retail environments are particularly susceptible to theft and fraud, and without proper screening, companies open themselves up to significant losses.

The article discusses key cybersecurity trends and challenges observed in 2024. Nation-state attacks have targeted the open-source ecosystem, making software supply chain attacks effective at bypassing sanctions. Basic bot attacks remain a major concern, with many businesses unprotected, leaving them vulnerable to DDoS attacks and fraud. Legacy networking and security architectures struggle with the distributed nature of users and applications while enterprises face a growing resource and skills gap.

WIRED explores how injectable GLP-1 drugs like Ozempic have been in high demand, treating diabetes, obesity, and providing cardiovascular benefits. After shortages in 2022, compounding pharmacies and telehealth clinics began offering oral versions of semaglutide and tirzepatide, claiming to deliver the same active ingredients without injections. However, these compounded versions have not been rigorously tested in clinical trials, and there is skepticism about their effectiveness.